Finance

Lists
USPH:NYSE
US Physical Therapy Inc
$77.71
0.00%
(0.00) 1D
$78.31
+0.77% (+0.60)
Pre-market
Closed: Sep 10, 4:00:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for USPH...
Mkt. cap
1.16B
Avg. vol.
198.33K
Volume
3.75K
Dividend
2.37%
Quarterly dividend
$0.46
Ex-dividend date
Aug 21, 2026
P/E ratio
442.19
52-wk high
$93.50
52-wk low
$58.19
EPS
$0.18
Beta
1.13
Shares outstanding
14.92M
No. of employees
6K
Mkt. cap
1.16B
Avg. vol.
198.33K
Volume
3.75K
Dividend
2.37%
Quarterly dividend
$0.46
Ex-dividend date
Aug 21, 2026
P/E ratio
442.19
52-wk high
$93.50
52-wk low
$58.19
EPS
$0.18
Beta
1.13
Shares outstanding
14.92M
No. of employees
6K
About US Physical Therapy Inc
CEO-
Employees6.37K
Founded1990
HeadquartersHouston, Texas, United States
SectorHealth care provider
Websiteusph.com
Analyst ratings
Based on 3 analysts giving stock ratings to USPH in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for USPH in the last 3 months.
Highest
Current $77.71
$98.00 (+26.11%)
Average
$93.00 (+19.68%)
Lowest
$88.00 (+13.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jared Haase
William Blair
Hold
Reiterated
-
-
08/14/2026
Michael Petusky
Barrington
Buy
Maintained
$98.00
+26.1%
08/10/2026
Joanna Gajuk
Bank of America Securities
Buy
Reiterated
$88.00
+13.2%
08/06/2026
Benjamin Rossi
J.P. Morgan
Buy
Maintained
$90.00
+15.8%
05/18/2026
Constantine Davides
Citizens JMP
Buy
Maintained
$98.00
+26.1%
05/08/2026
Jack Slevin
Jefferies
Buy
Reiterated
$102.00
+31.3%
03/09/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.75 / $0.82
-9.09%miss
Revenue / Est. (USD)
211.94M / 211.81M
+0.06%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
195.06M
201.00M
196.28M
211.94M
Cost of goods sold
152.73M
156.58M
157.94M
164.37M
Cost of revenue
152.73M
156.58M
157.94M
164.37M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.41M
18.12M
18.27M
18.37M
Operating expense
22.91M
22.41M
23.93M
23.99M
Total operating expenses
175.64M
178.99M
181.87M
188.36M
Operating income
19.42M
22.01M
14.41M
23.58M
Other non operating income
-441.00K
198.00K
494.00K
7.00K
EBT including unusual items
22.88M
14.96M
10.56M
19.05M
EBT excluding unusual items
16.96M
20.20M
12.49M
20.81M
Income tax expense
5.23M
5.78M
2.41M
4.16M
Effective tax rate
22.88%
38.66%
22.79%
21.81%
Other operating expenses
-
-
-
-
Net income
13.14M
4.15M
5.04M
9.90M
Net profit margin
6.74%
2.07%
2.57%
4.67%
Earnings per share
0.66
0.67
0.46
0.75
Interest and investment income
33.00K
20.00K
16.00K
29.00K
Interest expense
-2.41M
-2.35M
-2.79M
-3.21M
Net interest expenses
-2.38M
-2.33M
-2.78M
-3.18M
Depreciation and amortization charges
5.50M
4.28M
5.66M
5.62M
EBITDA
25.25M
26.64M
20.41M
29.52M
Gain or loss from assets sale
-18.00K
-37.00K
99.00K
203.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps